Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1–9. doi: 10.1016/j.ejca.2012.12.027.
   PubMed Web of Science ®Google Scholar
• Surveillance E, and End Results Program. Cancer stat facts: breast. 2023. Available from: https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• European Commission. Breast cancer burden in EU-27. 2020. Available from: https://ecis.jrc.ec.europa.eu/pdf/Breast_cancer_factsheet-Oct_2020.pdf
   Google Scholar
• The Global Cancer Observatory. GLOBOCAN - cancer fact sheet: Bulgaria. 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/100-bulgaria-fact-sheets.pdf
   Google Scholar
• He Y, Liu Z, Qiao C, et al. Expression and significance of WNT signaling components and their target genes in breast carcinoma. Mol Med Rep. 2014;9(1):137–143. doi: 10.3892/mmr.2013.1774.
   PubMed Web of Science ®Google Scholar
• Lamb R, Lehn S, Rogerson L, et al. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 2013;12(15):2384–2394. doi: 10.4161/cc.25403.
   PubMed Web of Science ®Google Scholar
• Shimoi T, Sagara Y, Hara F, et al. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer. 2020;27(3):340–346. doi: 10.1007/s12282-020-01054-7.
   PubMed Web of Science ®Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019.
   PubMed Web of Science ®Google Scholar
• Republic of Bulgaria. National council on prices and reimbursement of medicinal products. 2023. Available from: https://www.ncpr.bg/en/
   Google Scholar
• EMA. Ibrance: EPAR - product information [internet]. Amsterdam, Netherlands: EuropeanMedicines Agency; 2016. Last updated: 06/06/2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance
   Google Scholar
• EMA. Kisqali: EPAR - product information [internet]. Amsterdam, Netherlands: European Medicines Agency; 2017. Last updated: 25/08/2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali
   Google Scholar
• EMA. Verzenios: EPAR - product information [internet]. Amsterdam, Netherlands: European Medicines Agency; 2018. Last updated: 12/07/2023. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios
   Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi: 10.1056/NEJMoa1810527.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219. doi: 10.1056/NEJMoa1505270.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi: 10.1056/NEJMoa1609709.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123. doi: 10.1186/s13058-018-1050-7.
   PubMedGoogle Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. doi: 10.1093/annonc/mdy155.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–950. doi: 10.1056/NEJMoa2114663.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. doi: 10.1200/JCO.2018.78.9909.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32(8):1015–1024. doi: 10.1016/j.annonc.2021.05.353.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia SKL, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). J Clin Oncol. 2021;39(15):1001–1001. doi: 10.1200/JCO.2021.39.15_suppl.1001.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915. doi: 10.1016/S1470-2045(18)30292-4.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- Advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. doi: 10.1200/JCO.2017.73.7585.
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):5. doi: 10.1038/s41523-018-0097-z.
   PubMed Web of Science ®Google Scholar
• Boyang Z. Clinical data extraction and normalization of cyrillic electronic health records via deep-learning natural language processing. J Clin Oncol Clin Cancer Informatics. 2019;3:1–9.
   Google Scholar
• El-Khorazaty JA, Koch G, Preisser J. The iterative proportional fitting algorithm for adjusted agreement in a non-inferiority diagnostic clinical trial. Pharm Stat. 2014;13(3):173–178. doi: 10.1002/pst.1614.
   PubMed Web of Science ®Google Scholar
• Queiroz MM, Sacardo KP, Ribeiro MF, et al. Real-world treatment outcomes in HR + HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: results from a reference center in Brazil. Cancer Treat Res Commun. 2023;35:100683. doi: 10.1016/j.ctarc.2023.100683.
   PubMedGoogle Scholar
• García-Trevijano Cabetas M, Lucena Martínez P, Jiménez Nácher I, et al. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. Int J Clin Pharm. 2021;43(4):893–899. doi: 10.1007/s11096-020-01193-z.
   PubMed Web of Science ®Google Scholar
• Fernández-Cuerva C, Chinchilla-Alarcón T, Alcaraz-Sánchez JJ. Real-world effectiveness of ribociclib in metastatic breast cancer patients: does dose affect survival? J Oncol Pharm Pract. 2022;10781552221144280. doi: 10.1177/10781552221144280.
   Google Scholar
• Fountzilas E, Koliou GA, Vozikis A, et al. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the hellenic cooperative oncology group. ESMO Open. 2020;5(4):e000774. doi: 10.1136/esmoopen-2020-000774.
   PubMed Web of Science ®Google Scholar